NCT05556291View on ClinicalTrials.gov

Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study

CompletedOBSERVATIONAL
Enrollment

190

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

July 1, 2024

Study Completion Date

December 1, 2024

Conditions
EfficacySafetyTolerability
Interventions
DRUG

Combinations of Oral Blood Glucose Lowering Drugs

Combination of Ertugliflozin and Sitagliptin

Trial Locations (3)

75330

Doctor's Plaza, Karachi

Khan's Clinic, Karachi

PECHS, Karachi

Sponsors

Lead Sponsor

Getz Pharma
All Listed Sponsors
collaborator

Primary Care Diabetes Association, Pakistan

OTHER

lead

Getz Pharma

INDUSTRY

NCT05556291 - Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study | Biotech Hunter | Biotech Hunter